The development of new designer DNA drugs is on the anvil for rare diseases and neurodegenerative disorders like Alzheimer’s and Parkinson’s, but would these drugs be affordable for patients?
That is the big question as the pricing of the new drugs is becoming a contentious issue in all the countries, scientist and chair of the Cellular and Molecular Medicine, Dr Don Cleveland, said at the Bio-Asia Summit.
Dr Cleveland said, “Real beneficiaries of medicines are not able to achieve it because the pricing is not sensible. As scientists we have no control over that. The research in the United States is now done from the funds of the government or those given by philanthropic institutes. The amount of research done by pharmaceutical companies has seen a decline. Affordable pricing is important to ensure benefits reach those who need it most.”
The designer DNA drugs have shown good results in spinal muscular atrophy. SMA affects 1 in 11,000 live births and is a genetic disorder. These drugs produce sustained suppression of the target.
Dr Cleveland said, “The clinical trials have shown encouraging results and the children have survived. These drugs will play a major role in the future.”
Source- Deccan chronicle
Published on: February 27, 2019